References

Predictors of mortality in Staphylococcus aureus bacteremia

2021 · External reference

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

10.1086/421946 · 2004 · External reference

A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bactaraemia: an observational cohort study

10.1016/s1473-3099(14)70876-x · 2014 · External reference

Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus

10.1001/archinte.162.19.2229 · 2002 · External reference

Unresolved reference

External reference

Persistent Staphylococcus aureus bacteremia

10.1097/md.0b013e318289ff1e · 2013 · External reference

Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

10.1093/cid/ciq146 · 2011 · External reference

Defining persistent Staphylococcus aureus bacteremia: secondary analysis of a prospective cohort study

10.1016/s1473-3099(20)30447-3 · 2020 · External reference

Effect of vancomycin or daptomycin with vs without antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial

10.1001/jama.2020.0103 · 2020 · External reference

Unresolved reference

External reference

Persistent methicillin-resistant Staphylococcus aureus bacteremia: resetting the clock for optimal management

10.1093/cid/ciac364 · 2022 · External reference

Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome

10.1080/00365540500372846 · 2006 · External reference

Predictors of persistent methicillin-resistant staphylococcus aureus bacteraemia in patients treated with vancomycin

10.1093/jac/dkq050 · 2010 · External reference

Beta-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone

10.1128/aac.01204-13 · 2014 · External reference

Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia

10.1128/aac.02483-18 · 2019 · External reference

Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis

10.1002/phar.2034 · 2017 · External reference

Daptomycin plus beta lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study

10.1093/cid/ciz746 · 2020 · External reference

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline

10.1016/j.clinthera.2014.05.061 · 2014 · External reference

Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review

10.1093/ofid/ofx084 · 2017 · External reference

Ceftaroline as salvage monotherapy for persistent MRSA bacteremia

10.1177/1060028016664361 · 2016 · External reference

Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia

10.1002/phar.2741 · 2023 · External reference

Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia

10.1016/j.ijantimicag.2023.106735 · 2023 · External reference

Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity

10.1086/502156 · 2003 · External reference

Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort

10.1086/317421 · 2000 · External reference

Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility

10.1038/s41598-018-26277-9 · 2018 · External reference

Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections

10.1016/j.ijid.2017.05.010 · 2017 · External reference

Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments

10.1093/ofid/ofz538 · 2020 · External reference

Combination of vancomycin and beta-lactam therapy for MRSA bacteremia: a pilot multicenter randomized controlled trial

10.1093/cid/civ808 · 2016 · External reference

Monotherapy with vancomycin or daptomycin versus combination therapy with beta-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis

10.1007/s40121-020-00292-8 · 2020 · External reference

Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary

10.1093/cid/cir034 · 2011 · External reference

Persistent methicillin-resistant staphylococcus aureus bacteremia: host, pathogen, and treatment

10.3390/antibiotics12030455 · 2023 · External reference

Incidence, prevalence, and management of MRSA bacteremia across patient populations–a review of recent developments in MRSA management and treatment

10.1186/s13054-017-1801-3 · 2017 · External reference

Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis, a randomized clinical trial

10.1093/cid/ciaa1081 · 2021 · External reference